Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInventory AverageInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Unicycive Therapeutics (UNCY) Net Margin (2022 - 2023)

Unicycive Therapeutics filings provide 2 years of Net Margin readings, the most recent being 2187.7% for Q1 2023.

  • On a quarterly basis, Net Margin changed N/A to 2187.7% in Q1 2023 year-over-year; TTM through Dec 2023 was 4653.48%, a N/A change, with the full-year FY2023 number at 4653.48%, down 275464.0% from a year prior.
  • Net Margin hit 2187.7% in Q1 2023 for Unicycive Therapeutics, down from 584.33% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 584.33% in Q3 2022 to a low of 2187.7% in Q1 2023.